News

NIH Will Not Fund Gene-Editing Technologies in Human Embryos


 

References

NIH Director Francis S. Collins, MD, PhD, has announced that the agency will not fund gene-editing technologies in human embryos. The strong arguments against gene-editing, he said, include serious and unquantifiable safety issues, ethical issues that arise by altering human DNA in a way that can be inherited without consent of the next generation, and a current lack of compelling medical applications justifying the use of gene-editing techniques in embryos. Read the statement.

In related news, the National Academy of Sciences and the National Academy of Medicine are launching a major initiative to guide decision-making about research involving human gene editing. A multidisciplinary, international committee will be appointed to explore the associated scientific, ethical, and policy issues and recommend guidelines for gene-editing technologies.

http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=05182015

Recommended Reading

NORD to honor NIH Director and others at Portraits of Courage Celebration
MDedge Neurology
Neurologists describe how “cyberconsults” may help those training for rare disease careers
MDedge Neurology
AAN and AANEM publish guides for evaluation, diagnosis and management of Congenital Muscular Dystrophy (CMD)
MDedge Neurology
AAN: Largest neuroleptic malignant syndrome study finds predictors of poor outcome
MDedge Neurology
A New Symptomatic Treatment for Lambert-Eaton Myasthenic Syndrome?
MDedge Neurology
Research Illuminates Genetic Forms of Epilepsy
MDedge Neurology
Canada Adopts First-Ever Rare Disease Strategy
MDedge Neurology
NORD Issues Statement on Approval of 21st Century Cures Initiative and Introduction of OPEN Act
MDedge Neurology
Foundation for Prader-Willi Research and NORD Launch Global Registry
MDedge Neurology
NORD, EURORDIS, and Rare Disease Organizations in 30 Nations Announce an International Rare Diseases Alliance (copy 1)
MDedge Neurology